The development of this advanced ultrasound system represents a pivotal shift in how breast cancer screenings are approached. Traditional mammography, which relies on X-rays, is effective but has notable limitations. Specifically, it often fails to identify aggressive tumors that may develop in the interim between routine screenings, commonly referred to as interval cancers. These types of tumors account for a staggering 20 to 30 percent of all breast cancer diagnoses and are generally considered more insidious. The rise of interval cancers underscores the urgent need for more regular and accessible ultrasound screenings.

The MIT team envisions a future where individuals can easily adopt ultrasound as a routine monitoring tool, thereby detecting tumors earlier and ultimately boosting survival rates. Current screening practices often limit ultrasound use to follow-up evaluations after a mammogram reveals a potential concern. The conventional ultrasound machines employed in these situations are large and costly, necessitating specialized training to operate. Addressing these barriers, the MIT innovators, led by Canan Dagdeviren, aim to democratize access to this life-saving technology, particularly for underserved populations or those living in remote regions.

In developing this new ultrasound system, the team reimagined the design to include an array of ultrasound transducers arranged in a compact, user-friendly probe. This innovative configuration facilitates real-time imaging by capturing a wide-angle 3D view of breast tissue. It represents a significant advancement over previous attempts, as the new system only requires scanning at two or three specific locations to generate comprehensive 3D images without the gaps that might be a concern with 2D systems.

The portability of this new device cannot be overstated. Unlike its traditional counterparts, which often necessitate bulky, expensive equipment that is confined to healthcare facilities, this new ultrasound probe can be paired with a laptop for immediate data processing. This capability allows for the visualization of detailed images on the go, making regular screenings much more feasible for individuals who might otherwise face obstacles in accessing traditional healthcare services.

One of the most exciting aspects of this technology is its potential for reducing the power requirements associated with traditional ultrasound devices. The new system is engineered to operate efficiently on a simple 5V DC supply, such as that used for small electronics. This feature not only enhances portability but also expands the potential user base, as it can be powered by readily available sources, including batteries commonly used for mobile devices.

The researchers validated their new system through trials conducted on human subjects, achieving promising results. For instance, they successfully demonstrated that their device could produce accurate 3D imaging of breast cysts in a patient with a history of breast-related health issues. The ability of the system to image up to 15 centimeters deep into breast tissue while maintaining the integrity of the images is a crucial milestone in the field of medical imaging.

Looking ahead, the MIT team is dedicated to further refining their technology. They envision creating an even smaller version of the data processing system, potentially the size of a fingernail, which could eventually interface with smartphones. Such advancements could lead to the development of mobile applications that guide users in utilizing the ultrasound device effectively, ensuring optimal positioning for accurate imaging results.

The overarching goal of this groundbreaking research is to mitigate inequalities in health care access. By facilitating at-home use of ultrasound technology for women at high risk of developing breast cancer, the team aims to encourage more frequent monitoring and earlier detection of abnormalities. As the technology progresses, Dagdeviren has expressed a commitment to translating these innovations into commercial solutions, with ongoing support from various MIT initiatives geared toward healthcare advancements.

This novel ultrasound system marks a decisive step forward in breast cancer detection and monitoring. By moving ultrasound technology beyond the boundaries of hospitals and into community settings, this research has the potential to save lives and transform the approach to breast health in ways previously unimagined. With continuing clinical trials and a view toward commercialization, the future of personalized ultrasound screening appears bright.

The implications of this technology extend beyond individual health benefits; they represent a significant advancement in the fight against breast cancer. By minimizing barriers to access and creating a versatile, affordable solution, the MIT team not only paves the way for improved outcomes but also sets a precedent for the future of healthcare innovation. The next few years will be crucial as they further develop this technology and its applications, potentially bringing life-saving screening to women around the world.

As research in this area progresses, the team’s commitment to expanding access to ultrasound technology shines a light on the intersection of engineering and healthcare. By harnessing advancements in miniaturization and data processing, they have crafted a solution that respects both patient needs and logistical realities—one that is poised to make a profound impact on breast cancer detection and ultimately save countless lives.

As this technology continues to evolve, it will be essential for practitioners, patients, and the medical community at large to stay informed. The research team is optimistic about the potential implications for healthcare practices worldwide, aiming to ultimately transform how breast cancer is monitored and diagnosed across diverse populations, thus building a more equitable healthcare landscape.

The road ahead is filled with opportunities and challenges as they navigate the regulatory landscape and clinical environments. The commitment to innovation at MIT, driven by the tenacity of the researchers involved, ensures that this technology will continue to improve, reaching new heights in its capabilities and accessibility.

Mitigating the impact of breast cancer on women’s health requires the advocacy of healthcare practitioners and the integration of innovative technologies like this ultrasound system. As they prepare for broader clinical trials and potential commercialization, the role of patient education will be paramount in maximizing the effective use of this device.

Through continued advancements, public awareness, and collaboration within the medical community, this new direction in ultrasound technology could redefine routine breast health practices, ensuring that early detection and effective monitoring become standard for all women at risk of breast cancer.

Subject of Research:
Article Title: Real-Time 3D Ultrasound Imaging with an Ultra-Sparse, Low Power Architecture
News Publication Date: 29-Jan-2026
Web References: DOI Link
References: Advanced Healthcare Materials
Image Credits: Conformable Decoders Lab at the MIT Media Lab

Keywords

• Health and Medicine
• Diseases and disorders
• Cancer
• Breast cancer
• Ultrasound
• Medical technology
• Medical equipment
• Engineering
• Human health
• Clinical medicine
• Medical treatments
• Biomedical engineering

Conventional medical diagnostics often involve sending blood or tissue samples to centralized clinical laboratories, where specialized personnel perform intricate testing and data interpretation. This process can be time-consuming and costly, creating barriers for many patients, especially those who face logistical, financial, or geographical limitations in accessing healthcare facilities. Recognizing these challenges, the research team, led by graduate student Han Lee and Professor Brian Cunningham at the University of Illinois at Urbana-Champaign, set out to develop a solution that brings diagnostic power directly to the patient’s side.

Point-of-care testing refers to medical testing performed at or near the site of patient care, ranging from home settings to clinics or specialist appointments. By providing rapid, easy-to-use, and cost-effective diagnostic tools, these technologies enable clinicians and patients to make timely decisions that can dramatically improve health outcomes. Examples such as home pregnancy kits, at-home COVID-19 antigen tests, and blood glucose meters for diabetes management have already demonstrated how point-of-care devices can revolutionize healthcare delivery and patient autonomy.

The team’s breakthrough stems from advancing a cutting-edge biosensing technique originally reported in prior studies, called Photonic Resonator Absorption Microscopy—or PRAM. PRAM offers an unprecedented ability to detect individual biomarker molecules such as nucleic acids, antigens, and antibodies, which act as critical indicators of physiological or pathological states. Unlike many biosensors that measure the collective signal generated by thousands of molecules, PRAM achieves digital resolution by identifying single molecules, significantly enhancing detection sensitivity and diagnostic precision.

At its core, PRAM operates by shining red LED light onto a sophisticated photonic sensor where target molecules tagged with gold nanoparticles (AuNPs) bind to the surface. These AuNPs, minuscule particles approximately 1,000 times smaller than human hair, create detectable contrast spots against a red background when imaged. However, the raw images generated can be difficult to interpret because of the presence of artifacts such as dust, nanoparticle aggregates, or noise. Traditionally, accurately counting the true biomarker-related signals demands extensive expertise and manual adjustment of thresholding parameters, limiting the scalability and applicability of PRAM in everyday clinical use.

To overcome these challenges, Han Lee developed a novel integration of advanced machine learning algorithms with PRAM, pioneering a method termed Localization with Context Awareness (LOCA). This approach leverages deep learning techniques to automatically analyze PRAM images, accurately distinguishing genuine biomarker signals from artifacts, and enabling real-time, high-precision molecular detection. The incorporation of artificial intelligence dramatically reduces dependence on human expertise, facilitating point-of-care deployment by non-specialists and patients themselves.

Because machine learning models rely heavily on the quality of their training data, the researchers adopted an innovative validation strategy. Lee painstakingly imaged identical biomarker samples using both PRAM and scanning electron microscopy (SEM). SEM provides ultra-high-resolution images where individual AuNPs are clearly distinguishable, serving as a ground truth reference to annotate spots in the PRAM images precisely. This labor-intensive cross-validation process was akin to finding a needle in a haystack, requiring the creation of reference landmarks to reliably match image areas across the two different microscopy platforms.

The resulting dataset empowered the training of a physically grounded deep learning model capable of interpreting complex microscopic image features in PRAM while factoring in physical realities of nanoparticle behavior and sensor optics. When tested, LOCA-PRAM demonstrated remarkable improvements over conventional image analysis algorithms, exhibiting enhanced sensitivity in detecting lower biomarker concentrations and substantially reducing false-positive and false-negative rates. This leap in analytical performance opens the door to reliable and widespread clinical application of PRAM technology.

Professor Brian Cunningham emphasizes the clinical potential of rapid, point-of-care diagnostics powered by this technology. Physicians often encounter bacterial infections treated empirically with broad-spectrum antibiotics due to lack of rapid identification of the causative agent. LOCA-PRAM’s capability suggests a future where cancer patients could receive tailored therapeutic guidance during routine appointments, quickly determining the most effective anti-cancer drugs or monitoring treatment efficacy shortly after initiation. Such timely interventions could dramatically improve patient outcomes and reduce unnecessary side effects.

This project exemplifies how interdisciplinary collaboration—combining electrical and computer engineering, materials science, and biomedical research—can yield technologies that bridge fundamental science and clinical practice. The implementation of machine learning in biosensing not only exemplifies technical ingenuity but also reflects a commitment to addressing real-world healthcare disparities by enhancing diagnostic accessibility.

Han Lee’s journey highlights the transformative power of curiosity and cross-field learning. Inspired by a university course in machine learning, Lee independently explored how artificial intelligence could solve persistent image interpretation problems in biosensing. The result is not merely an academic advance but a potentially life-saving technology that contributes meaningfully to the evolution of personalized medicine and global health.

Published in the journal Biosensors and Bioelectronics, the study titled “Physically grounded deep learning-enabled gold nanoparticle localization and quantification in photonic resonator absorption microscopy for digital resolution molecular diagnostics” represents a significant milestone in biosensor development. Supported by prominent funding agencies including the National Institutes of Health, the USDA AFRI Nanotechnology grant, and the National Science Foundation, this research lays foundational work for next-generation diagnostic devices.

As the medical field moves towards more decentralized, patient-centered care, technologies like LOCA-PRAM could redefine how we detect, monitor, and manage diseases in real-time. This innovative blend of nanotechnology, photonics, and artificial intelligence heralds a new era of precision diagnostics—one where critical health information can be accessed rapidly and affordably, empowering both patients and practitioners alike. The implications for public health, especially in underserved communities, are profound and far-reaching.

Subject of Research: Biosensing technology, machine learning integration, and point-of-care molecular diagnostics

Article Title: Physically grounded deep learning-enabled gold nanoparticle localization and quantification in photonic resonator absorption microscopy for digital resolution molecular diagnostics

Web References: https://doi.org/10.1016/j.bios.2025.117455

References: Supported by National Institutes of Health, USDA AFRI Nanotechnology grant, and National Science Foundation

Image Credits: Julia Pollack

Keywords: Machine learning, Photonic crystals, Gold nanoparticles, Biomarkers, Medical diagnosis

The device functions through a microfluidic cartridge that collects saliva and utilizes a lateral flow assay embedded within a polymer lab-on-a-chip. Once the patient inserts this cartridge into a compact reader, the system quickly analyzes cortisol concentration, transmitting the data directly to smartphones or portable analyzers for immediate review. This capability is particularly transformative because it enables patients to conduct their own testing outside of clinical environments, facilitating real-time monitoring and convenient sharing of results with healthcare providers through web-based applications.

Mental health disorders, notably anxiety and depression, afflict over 400 million individuals worldwide and rank among the leading causes of disability globally. The hormone cortisol, often referred to as the “stress hormone,” plays a critical role in the body’s response to stress; however, sustained elevated cortisol levels have been closely linked to the pathophysiology of several mental health conditions. Traditional mental health assessments rely heavily on patient self-reporting, which can suffer from bias or underreporting. This new device provides an objective biochemical marker to supplement these evaluations, enhancing the precision of diagnoses.

The design combines microfabrication techniques with biochemical assay principles, integrating microchannels and sensitive detection reagents within a compact polymer chip. This enables rapid reaction kinetics and precise quantification of cortisol through lateral flow immunoassays, a method analogous in simplicity to common pregnancy tests but with advanced detection capabilities. The entire process from sample collection to result transmission is streamlined to take place within minutes, offering unprecedented speed for stress hormone profiling.

Co-author and doctoral candidate Supreeth Setty is expanding on this foundation by investigating dehydroepiandrosterone (DHEA), a hormone known to counterbalance the effects of cortisol. The ratio between cortisol and DHEA in saliva can serve as a more detailed biomarker for chronic stress conditions, providing clinicians nuanced insights into a patient’s endocrine status. This additional layer of testing could refine mental health assessments and help tailor personalized intervention strategies.

Setty emphasizes that the major advantage of point-of-care testing lies in its practicality and accessibility, reducing the delays typically associated with lab-based analyses. By furnishing immediate results, medical professionals can make quicker clinical decisions, which is vital in urgent mental health scenarios. Moreover, the objective data acts as a powerful supplement to psychometric questionnaires, often limited by patients’ variable self-awareness or reluctance to disclose symptoms.

The ongoing research efforts plan to move beyond prototype validation towards extensive clinical trials involving psychiatrists and mental health practitioners. Such collaborative endeavors aim to confirm the clinical utility of this platform in diverse patient populations, evaluating its accuracy, reproducibility, and overall impact on healthcare workflows. Success in these stages could pave the way for widespread adoption and integration into both primary care and specialized psychiatric services.

Interestingly, the researchers have also extended the principle of this technology to other critical biomarkers, notably cardiac troponin. Troponin levels rise sharply in the bloodstream following myocardial damage, a key diagnostic indicator of heart attacks. Through a similar point-of-care biochemical test capable of analyzing a single drop of blood, physicians could monitor cardiac health more continuously and respond swiftly to acute events, potentially improving patient outcomes by facilitating early interventions.

In addition, the UC team has ventured into infectious disease diagnostics by engineering a new testing platform aimed at rapid COVID-19 detection. Drawing from their experience in microfluidics and lateral flow assays, this platform enhances sensitivity and turnaround times, making it well suited for widespread screening applications during pandemics or localized outbreaks. The adaptability of their lab-on-a-chip approaches underscores the broad potential of their technological innovations across diverse fields of medical diagnostics.

Professor Chong Ahn highlights the urgent need for advances in mental health care technology, particularly given the increasing global burden of stress-related disorders. “Mental health care can be an urgent situation. And so these tests will help doctors make timely interventions,” he states. By empowering patients with tools for self-testing and enabling clinicians with objective biochemical data, these devices could revolutionize mental healthcare delivery, bridging gaps in accessibility and diagnostic precision.

The development of portable, user-friendly point-of-care platforms represents a paradigm shift from centralized laboratory testing towards decentralized, patient-centric health monitoring. Such advancements align with broader trends in digital health, personalized medicine, and telehealth services. As healthcare systems grapple with expanding demand and resource constraints, technologies like this lab-on-a-chip device offer scalable solutions that maintain clinical rigor while enhancing convenience.

Through continued innovation in microengineering and biosensing, the University of Cincinnati researchers are at the forefront of transforming how stress biomarkers are detected and leveraged clinically. Their combined expertise in engineering, chemistry, and clinical collaboration exemplifies the interdisciplinary approach needed to address complex health challenges. If successful, this innovation not only promises improved mental health diagnostics but also signals a new era in point-of-care biochemical testing that could impact multiple domains of medicine.

—

Subject of Research: Point-of-care biochemical testing for mental health and cardiac biomarkers using microfluidic lab-on-a-chip technology

Article Title: On-site analysis of cortisol in saliva based on microchannel lateral flow assay on polymer lab-on-a-chip

News Publication Date: 10-Apr-2025

Web References:
– https://link.springer.com/article/10.1007/s10544-025-00733-6
– https://pubs.acs.org/doi/full/10.1021/acs.analchem.4c06427
– https://pubs.rsc.org/en/content/articlelanding/2025/sd/d4sd00352g

Image Credits: Andrew Higley

Keywords: Psychiatry, Point-of-care testing, Lab-on-a-chip, Cortisol, Mental health diagnostics, Microfluidics, Stress biomarkers, Depression, Anxiety, Cardiac troponin, COVID-19 diagnostics